Via Medica Journals
Not a member yet
55128 research outputs found
Sort by
Predictors of atrial fibrillation recurrence following a successful electrical cardioversion — narrative review
No full textSinus rhythm (SR) maintenance strategies after electrical or pharmacological cardioversion in patients with atrial fibrillation (AF) may be only temporarily effective, leading to AF recurrence. Identifying predictors of AF recurrence after effective electrical cardioversion (ECV) may help personalize treatment, for instance, by affecting modifiable factors of unsuccessful long-term rhythm control. Disseminating information on this topic may benefit individual patients, lower the risk of subsequent procedures and the associated complications, and decrease health care costs. The purpose of this paper was to present the current state of knowledge on the predictors of failed ECV, with a particular focus on the most recent relevant research
Beyond the guidelines. Advanced endovascular therapies in a most challenging aortic coarctation case
No full textThe efficacy and safety of pyrotinib in treating HER2-positive metastatic breast cancer patients: a multicenter study
No full textIntroduction. To evaluate the clinical outcomes and safety profile of pyrotinib in HER2-positive metastatic breast cancer (MBC) patients.
Material and methods. This is a multicenter retrospective study. Eligible enrolled HER2-positive MBC patients who received pyrotinib-containing regimens were included in the study. Efficacy endpoints comprised objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS). Adverse events (AEs) were systematically recorded.
Results. Among 275 enrolled females (median age 57 years), ORR and DCR were 56% (154/275) and 75% (205/275), respectively. With a median follow-up of 41 months, median PFS and OS reached 16 and 35 months. The 1-year, 2-year, and 3-year PFS rates for the general population were 72.7%, 40.4%, and 33.1%, respectively, whereas the OS rates were 91.6%, 78.2%, and 63.2%, respectively. For patients with brain metastases, the 1-year, 2-year, and 3-year PFS rates were 67.3%, 25%, and 13.5%, respectively, whereas the OS rates were 84.6%, 63.5%, and 46.2%, respectively. Treatment-related adverse effects (AEs) occurred in 93 patients (34%), with 13 discontinuing therapies due to toxicity.
Conclusions. Pyrotinib monotherapy demonstrated comparable efficacy to combination regimens in HER2-positive MBC management, with favorable safety outcomes, supporting its clinical application
Beyond recurrence — a 47-year journey of long-term survival in Ewing's sarcoma with late complications
No full textThe prognosis for patients diagnosed with Ewing's sarcoma (EwS) substantially improved since the integration of chemotherapy (CHT) into treatment protocols in the early 1970s. In the preceding series, the 5-year overall survival rate was documented to be approximately 10%, while in the recent ones it ranges between 75% and 80%. Consequently, the reports of very long-term survivors (≥ 30 years post-treatment) are scarce, particularly in cases where secondary malignancies and pathological fractures are present. Therefore, we present the case of the longest (to our knowledge) survival in EwS reported to date.
An 18-year-old female presented with a 10 × 7 × 7 cm tumor, which was identified as EwS following the biopsy. The tumor, located in the thigh, was associated with infiltration of lymph nodes and blood vessels. After surgical resection in September 1978, the patient received adjuvant CHT according to ROSEN protocol (dactinomicin, doxorubicin, cyclophosphamide and vincristine) and adjuvant radiotherapy (RT). The doses of CHT were adjusted due to grade 3–4 leukopenia. The patient completed adjuvant treatment by September 1980. In April 1980, doxorubicin was withdrawn upon reaching the cumulative dose of 775 mg. Despite complications including pathological fractures, the patient showed no evidence of disease recurrence on imaging follow-up. Over the years, the patient underwent several surgical procedures, including a mastectomy for ductal carcinoma in situ and resection for a basal cell adenoma of the hard palate. Throughout this period, regular follow-up imaging showed no recurrence or metastatic disease. As of early 2025, the patient remains alive with no evidence of disease progression or recurrence, marking a 47-year survival.
The long-term bone sarcoma survivors require vigilant, lifelong screening and care, as they are at risk of relapse, secondary neoplasms and pathological fractures, particularly during certain biological events, including pregnancy
Life on the edge: Unoperated tetralogy of Fallot in adults — a testimony to the remarkable endurance of the heart
No full textTranscatheter correction of interrupted aortic arch in a young woman with extensive collateral circulation
No full textLeczenie chorych na przerzutowego raka prostaty — obecna sytuacja
No full textProstate cancer is the most common malignancy and the second reason of cancer mortality in men in Poland. Treatment with new drugs, especially early intensification of treatment allows maximazing treatment benefits like gain in survival parameters. Availability of new drugs has clearly improved in the recent years but we can’t administer all drugs reccomended by the bigest oncology societies, while they are available in some Uropean Union countries. This article presents current treatment options for patients with metastatic prostatę cancer in Poland and areas which can be improved.Rak gruczołu krokowego jest w Polsce najczęstszym nowotworem złośliwym oraz drugą przyczyną zgonów nowotworowych u mężczyzn. Zastosowanie nowoczesnych metod leczenia (zwłaszcza intensyfikacja leczenia na wczesnym etapie choroby) umożliwia uzyskanie maksymalnych korzyści, co przekłada się na poprawę w zakresie parametrów przeżycia. W ostatnich latach dostęp do nowoczesnych leków uległ znaczącej poprawie, jednak wciąż brakuje części preparatów zalecanych przez towarzystwa onkologiczne, które są dostępne w innych krajach Unii Europejskiej.
W niniejszym artykule przedstawiono obecne możliwości leczenia chorych z zaawansowanym rakiem gruczołu krokowego w Polsce oraz dalsze kierunku rozwoju
Całkowita regresja zmian nowotworowych u chorego na zaawansowanego raka gruczołowego płuca bez ekspresji PD-L1 poddanego immunochemioterapii z wykorzystaniem niwolumabu i ipilimumabu
No full textThe introduction of immune checkpoint inhibitors has represented a breakthrough in the treatment of patients with advanced non-small cell lung cancer (NSCLC). The CheckMate 9LA trial, which used nivolumab plus ipilimumab plus 2 cycles of platinum-based chemotherapy, showed a significant improvement in overall survival and response time compared with 4 cycles of chemotherapy alone.
This paper presents the case of a 66-year-old patient with advanced lung adenocarcinoma without programmed cell death ligand 1 (PD-L1) expression, treated with immunochemotherapy with nivolumab and ipilimumab, in whom complete regression of neoplastic lesions was achieved.Wprowadzenie inhibitorów punktów kontrolnych układu odpornościowego stanowiło przełom w leczeniu chorych na niedrobnokomórkowego raka płuca (NDRP) w stadium zaawansowanym. W badaniu CheckMate 9LA, w którym zastosowano niwolumab i ipilimumab z 2 cyklami chemioterapii w oparciu o pochodną platyny, wykazano istotny zysk w przeżyciach całkowitych oraz czasie odpowiedzi na leczenie w stosunku do 4 cykli samodzielnej chemioterapii.
W pracy przedstawiono przypadek 66-letniego chorego na zaawansowanego raka gruczołowego płuca bez ekspresji liganda programowanej śmierci komórki typu 1 (PD-L1, programmed-cell death ligand 1) poddanego immunochemioterapii z wykorzystaniem niwolumabu i ipilimumabu, u którego uzyskano całkowitą regresję zmian nowotworowych
Nanoparticles in targeted breast cancer therapy — advances and challenges
No full textIntroduction. Breast cancer remains one of the most commonly diagnosed malignancies among women globally and represents a leading cause of cancer-related mortality. Conventional treatment modalities, including chemotherapy and radiotherapy, are often limited by low specificity and systemic toxicity. In recent years, nanoparticle-based strategies have emerged as promising alternatives due to their targeted drug delivery capabilities.
Material and methods. This narrative review synthesizes current research on the use of nanoparticles — specifically albumin- and chitosan-based nanocarriers — in breast cancer therapy. A comprehensive literature search was conducted using PubMed and Scopus databases, covering publications from 2010 to 2024. Articles were selected based on their relevance to mechanisms of drug delivery, nanocarrier design, therapeutic performance, and clinical applicability.
Results. Nanoparticles exploit both passive targeting mechanisms, such as the enhanced permeability and retention (EPR) effect, and active strategies involving ligand-receptor interactions. Albumin-based nanoparticles enhance the solubility of chemotherapeutics and facilitate their controlled release. Chitosan-based nanoparticles, due to their pH-sensitive behavior and high biocompatibility, allow functional customization and increased drug accumulation at tumor sites. These systems show potential in overcoming traditional limitations of breast cancer treatment, including poor drug penetration and systemic toxicity.
Conclusions. The implementation of nanoparticle-based systems in breast cancer therapy may lead to more effective and personalized treatment options. Despite significant advances, clinical translation is hindered by challenges related to stability, immunogenicity, and large-scale production. Continued research is essential to optimize nanocarrier performance and ensure their integration into modern oncologic practice
